Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 251–275 of 688 studies in Prevention trials · tagged Lifestyle (page 11 of 28) · 32,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Prevention trials” covers

Prevention trials — Trials that test whether a specific diet, lifestyle change or supplement actually slows cognitive decline.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

In multi-adjusted models, higher adherence to the EAT-Lancet diet was associated with higher total mean cortical thickness, and thicker cortex in Alzheimer's disease-signature regions, while a higher adherence to the MeDi was associated with better cognitive performance. 5 key findings →

Design: cohort study Participants: 615 Evidence: moderate

Vision difficulty and a larger friend network were negatively associated with adherence. 5 key findings →

Design: randomized controlled trial Participants: 191 Evidence: high

Preliminary evidence suggests that protective effects of the MIND diet are geographically generalizable. 2 key findings →

Participants: 1,220 Evidence: moderate

The purpose of this study is to examine the effects of the selected non-pharmacological lifestyle activities on the delay of cognitive decline in normal aging. 1 key finding →

Design: longitudinal study Evidence: high

In line with data from elderly population samples, Mediterranean and MIND diet and some data-derived dietary patterns were related to memory and language function. 5 key findings →

Design: cross-sectional Participants: 60 Evidence: moderate

Combined low plasma Aβ 42 /Aβ 40 ratio and high plasma NfL level was associated with greater declines in cognition and gait speed over time, providing further evidence of the links between cognitive and physical function. 5 key findings →

Design: cross-sectional Participants: 452 Evidence: moderate

Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2022-10-12

The aim of this study was to investigate whether adherence to conventional dietary recommendations or to a modified Mediterranean diet are associated with a subsequent lower risk of developing all-cause dementia, Alzheimer disease (AD), vascular dementia (VaD), or with future accumulation of AD-related β-amyloid (Aβ) pathology. 5 key findings →

Participants: 738 Evidence: low

Oldest-old eating less and having diets with less variety and nutrient density were more frequent among subjects with dementia. 4 key findings →

Design: cross-sectional Participants: 1,390 Evidence: moderate

Copenhagen Consensus statement 2019: physical activity and ageing

✓ Peer-reviewed alzhub usefulness score 60 out of 100. British journal of sports medicine 2019-02-21

This statement presents the consensus on the effects of physical activity on older adults' fitness, health, cognitive functioning, functional capacity, engagement, motivation, psychological well-being and social inclusion. 5 key findings →

Design: longitudinal study Evidence: high

Data collection commenced in November 2023 and finished in July 2024, with the enrollment of 49 older adults with MCI (n=40, 81.6%, assigned to the experimental group [EG] and n=9, 18.4%, to the control group [CG]) conducted from October 2023 to April 2024. 5 key findings →

Design: randomized controlled trial Participants: 40 Evidence: high

The CITA GO-ON Study, as a part of the World-Wide FINGERS network, is designed to validate the efficacy of a multidomain lifestyle intervention for dementia prevention and contribute valuable data to inform public health strategies fostering healthy, active aging. 3 key findings →

Design: randomized controlled trial Participants: 1,051 Evidence: high

Adherence to the Mediterranean Diet is Associated with Better Sleep Quality in Italian Adults

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Nutrients 2019-04-28

In an additional analysis stratifying the sample by weight status, the association between sleep quality and high adherence to the Mediterranean diet was observed only among normal/overweight individuals but not in obese participants. 3 key findings →

Participants: 1,936 Evidence: moderate

This cross-sectional study found a strong correlation between age of onset of PD and dietary habits, suggesting that nutritional strategies may be an effective tool to delay PD onset. 4 key findings →

Design: cross-sectional Participants: 167 Evidence: low

Mediterranean diet and cognitive function: From methodology to mechanisms of action

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Free radical biology & medicine 2021-09-22

The traditional Mediterranean diet (MedDiet), rich in minimally processed plant foods and fish, has been widely recognized to be one of the healthiest diets. 3 key findings →

Design: longitudinal study Evidence: high

The MIND diet is associated with both higher cognition and slower rates of cognitive decline, after controlling for neuropathology, indicating the MIND diet may be important to cognitive resilience. 3 key findings →

Design: longitudinal study Evidence: moderate

Closer Mediterranean diet adherence was associated with lower risk of cognitive impairment but not slower decline in cognitive function. 5 key findings →

Participants: 7,756 Evidence: high

Higher vitamin D dietary intake was associated with a lower risk of developing AD among older women. 5 key findings →

Design: cohort study Participants: 70 Evidence: moderate

A randomised controlled trial of physical activity and cognitive training in older adults: the PhABHeaD study

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Trials 2026-05-07

If a substantial synergetic effect is detected, it may lead to the use of more widespread concurrent physical and cognitive training and the potential development of methods to make concurrent training practical. 4 key findings →

Design: randomized controlled trial Participants: 126 Evidence: high

In the UK Biobank cohort (N = 166,916), MIND diet demonstrated the broadest neuroprotective effects. 5 key findings →

Design: prospective cohort Participants: 166,916 Evidence: high

This study examined the combined effects of StrongerMemory program (brain exercises involving reading, writing, and math) and weekly social engagement on cognitive, behavioral, and emotional outcomes in older adults with subjective cognitive decline (SCD). 4 key findings →

Design: randomized controlled trial Participants: 50 Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 32,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,580 records, built mostly from automated pulls of Europe PMC (66.9% of the library) and OpenAlex (15.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated